AnteoTech (ADO) investor relations material

Executive summary

• Achieved significant progress in life sciences and advanced battery technology, focusing on commercialization, expanding the commercial pipeline, and leveraging a proprietary platform with 17 granted patents.

• Enhanced organizational systems, skills, and team capabilities, positioning for stronger execution in 2027.

• Expanded product portfolio and clarified value propositions, targeting global markets in diagnostics and battery technologies.

• Increased market presence and engagement with institutional investors and brokers, especially in the U.S., Europe, and South Korea.

• Emphasized a capital-light, partnership-driven approach to scale globally.

Financial highlights

• FY 2026 sales revenue declined year-over-year due to timing of a major order and other timing factors; total revenue for FY 2026 was $3,129,144.

• Operating expenses reduced to $6,857,881 in FY2026, reflecting a focus on cost effectiveness and continuous improvement.

• Net loss for FY2026 was $5,375,654, an improvement from $6,759,135 in FY2025.

• Announced an R&D tax rebate of AUD 1.9 million to be booked in FY 2027.

• Losses were presented in a three-year trend, with ongoing efforts to improve financial discipline.

Outlook and guidance

• FY2027 priorities include converting customer evaluations into sales across India, US, Europe, Japan, and South Korea.

• Focus on progressing strategic partnerships, especially in CLIA and ELISA markets, and expanding battery technology sales.

• Sales execution and conversion are top priorities for FY 2027, with a curated pipeline of qualified leads and samples under evaluation.

• Anticipates further validation and commercial progress in both segments, with updates expected in the coming year.

• Continued financial discipline and support for sales pipeline conversion.